株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アブレーション装置:医療機器のパイプライン評価

Ablation Equipments - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 346490
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.08円で換算しております。
Back to Top
アブレーション装置:医療機器のパイプライン評価 Ablation Equipments - Medical Devices Pipeline Assessment, 2019
出版日: 2019年02月14日 ページ情報: 英文 107 Pages
概要

当レポートでは、アブレーション装置のパイプライン製品の各開発段階における比較分析などの詳細情報やパイプライン製品の開発に携わっている主な企業 (組織) の概要、現在治験が進行中のパイプライン製品の情報などを提供しています。

第1章 目次

第2章 イントロダクション

  • アブレーション装置の概要

第3章 開発中の製品

  • アブレーション装置 - 開発段階別のパイプライン製品
  • アブレーション装置 - 国 (地域) 別のパイプライン製品
  • アブレーション装置 - 規制別のパイプライン製品
  • アブレーション装置 - 認証時期別 (推定) のパイプライン製品
  • アブレーション装置 - 現在進行中の治験

第4章 アブレーション装置 - 開発中のパイプライン製品:企業別

  • アブレーション装置企業 - 開発段階別のパイプライン製品
  • アブレーション装置 - 開発段階別のパイプライン製品

第5章 アブレーション装置企業と製品の概要

  • AngioDynamics, Inc.の企業概要
    • AngioDynamics, Inc. - パイプライン製品と現在進行中の治験の概要
  • AtriCure, Inc.の企業概要
    • AtriCure, Inc. - パイプライン製品と現在進行中の治験の概要
  • CPSI Biotechの企業概要
    • CPSI Biotech - パイプライン製品と現在進行中の治験の概要
  • EP Global Communications, Inc.の企業概要
    • EP Global Communications, Inc. - パイプライン製品と現在進行中の治験の概要
  • HistoSonics, Inc.の企業概要
    • HistoSonics, Inc. - パイプライン製品と現在進行中の治験の概要
  • Hospital for Special Surgeryの企業概要
    • Hospital for Special Surgery - パイプライン製品と現在進行中の治験の概要
  • Innoblative Designs, Inc.の企業概要
    • Innoblative Designs, Inc. - パイプライン製品と現在進行中の治験の概要
  • Integra LifeSciences Holdings Corporationの企業概要
    • Integra LifeSciences Holdings Corporation - パイプライン製品と現在進行中の治験の概要
  • Intratherm, Llcの企業概要
    • Intratherm, Llc - パイプライン製品と現在進行中の治験の概要
  • Medtronic plcの企業概要
    • Medtronic plc - パイプライン製品と現在進行中の治験の概要
  • Mirabilis Medica, Inc.の企業概要
    • Mirabilis Medica, Inc. - パイプライン製品と現在進行中の治験の概要
  • Northwestern Universityの企業概要
    • Northwestern University - パイプライン製品と現在進行中の治験の概要
  • Prosurg, Inc.の企業概要
    • Prosurg, Inc. - パイプライン製品と現在進行中の治験の概要
  • Sanarus Technologies, LLCの企業概要
    • Sanarus Technologies, LLC - パイプライン製品と現在進行中の治験の概要
  • Smith & Nephew Plcの企業概要
    • Smith & Nephew Plc - パイプライン製品と現在進行中の治験の概要
  • Thermedical, Inc.の企業概要
    • Thermedical, Inc. - パイプライン製品と現在進行中の治験の概要
  • TransEnterix, Inc.の企業概要
    • TransEnterix, Inc. - パイプライン製品と現在進行中の治験の概要
  • University of California, San Franciscoの企業概要
    • University of California, San Francisco - パイプライン製品と現在進行中の治験の概要
  • University of Texas at Austinの企業概要
    • University of Texas at Austin - パイプライン製品と現在進行中の治験の概要
  • University of Wisconsin-Stoutの企業概要
    • University of Wisconsin-Stout - パイプライン製品と現在進行中の治験の概要

第6章 アブレーション装置 - 最近の動向

第7章 付録

図表

List of Tables

  • Table 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 2: Ablation Equipments - Pipeline Products by Territory
  • Table 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Table 5: Ablation Equipments - Ongoing Clinical Trials
  • Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development
  • Table 7: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: NanoKnife 3.0 - Product Status
  • Table 10: NanoKnife 3.0 - Product Description
  • Table 11: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
  • Table 12: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
  • Table 13: NanoKnife System - Pancreatic Cancer - Product Status
  • Table 14: NanoKnife System - Pancreatic Cancer - Product Description
  • Table 15: NanoKnife System - Prostate Cancer - Product Status
  • Table 16: NanoKnife System - Prostate Cancer - Product Description
  • Table 17: AngioDynamics Inc - Ongoing Clinical Trials Overview
  • Table 18: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer
  • Table 19: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study
  • Table 20: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
  • Table 21: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
  • Table 22: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety
  • Table 23: NanoKnife System - Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
  • Table 24: NanoKnife System - Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
  • Table 25: NanoKnife System - Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study
  • Table 26: NanoKnife System - Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial
  • Table 27: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
  • Table 28: NanoKnife System - Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer
  • Table 29: NanoKnife System - Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma
  • Table 30: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
  • Table 31: NanoKnife System - Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial
  • Table 32: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
  • Table 33: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
  • Table 34: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study
  • Table 35: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
  • Table 36: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
  • Table 37: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
  • Table 38: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
  • Table 39: NanoKnife 3.0 - The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses
  • Table 40: Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Fiber - Optic Laser - Product Status
  • Table 42: Fiber - Optic Laser - Product Description
  • Table 43: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: Pressurized Sub-Cooled Nitrogen System - Product Status
  • Table 45: Pressurized Sub-Cooled Nitrogen System - Product Description
  • Table 46: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status
  • Table 47: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description
  • Table 48: Creo Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Flexible Ablation System - Product Status
  • Table 50: Flexible Ablation System - Product Description
  • Table 51: Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: BoneCut Collaborative Robot - Product Status
  • Table 53: BoneCut Collaborative Robot - Product Description
  • Table 54: Elesta srl Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: EchoLaser - Product Status
  • Table 56: EchoLaser - Product Description
  • Table 57: EchoLaser EVO SoracteLite - Product Status
  • Table 58: EchoLaser EVO SoracteLite - Product Description
  • Table 59: Elesta srl - Ongoing Clinical Trials Overview
  • Table 60: EchoLaser - Transperineal Laser Ablation for Treatment of LUTS due to Benign Prostatic Obstruction
  • Table 61: Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Next Generation Ablation Catheter - Product Status
  • Table 63: Next Generation Ablation Catheter - Product Description
  • Table 64: Eximo Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: B-Laser - Gastrointestinal Procedures - Product Status
  • Table 66: B-Laser - Gastrointestinal Procedures - Product Description
  • Table 67: ExpandoHeat LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: Catheter Device - Tissue Ablation - Product Status
  • Table 69: Catheter Device - Tissue Ablation - Product Description
  • Table 70: Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 71: Revita DMR System - Product Status
  • Table 72: Revita DMR System - Product Description
  • Table 73: Fractyl Laboratories Inc - Ongoing Clinical Trials Overview
  • Table 74: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study
  • Table 75: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes
  • Table 76: Revita DMR System - Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)
  • Table 77: Revita DMR System - Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes
  • Table 78: Revita DMR System - Multicenter Clinical Trial of Revita DMR Procedure in Patients with Diabetes
  • Table 79: Revita DMR System - Randomized, Double-blind, Sham-controlled, Prospective, Multi-center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita System in the Treatment of Type 2 Diabetes
  • Table 80: Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 81: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Status
  • Table 82: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Description
  • Table 83: Harmonic Medical Inc - Ongoing Clinical Trials Overview
  • Table 84: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas.
  • Table 85: HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: Vortx RX - Product Status
  • Table 87: Vortx RX - Product Description
  • Table 88: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview
  • Table 89: Radiofrequency Ablation Device - Product Status
  • Table 90: Radiofrequency Ablation Device - Product Description
  • Table 91: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 92: Vision MR Ablation Catheter - Product Status
  • Table 93: Vision MR Ablation Catheter - Product Description
  • Table 94: Imricor Medical Systems Inc - Ongoing Clinical Trials Overview
  • Table 95: Vision MR Ablation Catheter - Cardiovascular Magnetic Resonance-guided Radiofrequency-ablation for Atrial Flutter
  • Table 96: Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview

List of Figures

  • Figure 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Figure 2: Ablation Equipments - Pipeline Products by Territory
  • Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Figure 5: Ablation Equipments - Ongoing Clinical Trials
目次
Product Code: GDME0715EPD

GlobalData's Medical Devices sector report, "Ablation Equipments - Medical Devices Pipeline Assessment, 2019" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Ablation Equipments under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ablation Equipments under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Ablation Equipments Overview

3 Products under Development

  • 3.1 Ablation Equipments - Pipeline Products by Stage of Development
  • 3.2 Ablation Equipments - Pipeline Products by Territory
  • 3.3 Ablation Equipments - Pipeline Products by Regulatory Path
  • 3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date
  • 3.5 Ablation Equipments - Ongoing Clinical Trials

4 Ablation Equipments - Pipeline Products under Development by Companies

  • 4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development
  • 4.2 Ablation Equipments - Pipeline Products by Stage of Development

5 Ablation Equipments Companies and Product Overview

  • 5.1 AngioDynamics Inc Company Overview
  • 5.2 Avenda Health Inc Company Overview
  • 5.3 CPSI Biotech Company Overview
  • 5.4 Creo Medical Ltd Company Overview
  • 5.5 Deneb Medical SL Company Overview
  • 5.6 Elesta srl Company Overview
  • 5.7 Ethicon US LLC Company Overview
  • 5.8 Eximo Medical Ltd Company Overview
  • 5.9 ExpandoHeat LLC Company Overview
  • 5.10 Fractyl Laboratories Inc Company Overview
  • 5.11 Harmonic Medical Inc Company Overview
  • 5.12 HistoSonics Inc Company Overview
  • 5.13 Hospital for Special Surgery Company Overview
  • 5.14 Imricor Medical Systems Inc Company Overview
  • 5.15 Innoblative Designs, Inc. Company Overview
  • 5.16 Integra LifeSciences Holdings Corp Company Overview
  • 5.17 Intratherm LLC (Inactive) Company Overview
  • 5.18 Massachusetts Institute of Technology Company Overview
  • 5.19 Medtronic plc Company Overview
  • 5.20 Memorial Sloan Kettering Cancer Center Company Overview
  • 5.21 Mirabilis Medical Inc Company Overview
  • 5.22 ProstaCare Pty Ltd Company Overview
  • 5.23 Pulse Biosciences Inc Company Overview
  • 5.24 Sabanci University Nanotechnology Research and Application Center Company Overview
  • 5.25 Southern Illinois University Carbondale Company Overview
  • 5.26 Thermedical Inc Company Overview
  • 5.27 TransEnterix Inc Company Overview
  • 5.28 University of California San Francisco Company Overview
  • 5.29 University of Texas at Austin Company Overview
  • 5.30 University of Wisconsin-Stout Company Overview

6 Ablation Equipments- Recent Developments

  • 6.1 Jul 19, 2018: Olympus names new director of medical and surgical business for the UK and Ireland
  • 6.2 Jul 19, 2018: Misonix appoints Gwen Watanabe as board director
  • 6.3 Jul 11, 2018: AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results
  • 6.4 Jul 10, 2018: Stryker announces organizational changes
  • 6.5 Jul 05, 2018: SonaCare reports long-term results of HIFU therapy for prostate cancer
  • 6.6 Jun 23, 2018: Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH
  • 6.7 Jun 14, 2018: HSS Hip and Knee Surgeon Bradford Waddell, MD, Named Chair of Young Arthroplasty Group
  • 6.8 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value
  • 6.9 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
  • 6.10 May 08, 2018: Smith & Nephew: Change of Directorate
  • 6.11 May 07, 2018: 'New era' for lung cancer patients
  • 6.12 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
  • 6.13 May 07, 2018: Integra LifeSciences Announces Amendment and Extension of Credit Facility
  • 6.14 May 07, 2018: Misonix Reports Record Third Quarter Revenue
  • 6.15 May 03, 2018: Smith & Nephew First Quarter 2018 Trading Report
  • 6.16 Apr 30, 2018: HSS Surgeon Michael L. Parks, MD, Named President of Orthopaedic Research and Education Foundation
  • 6.17 Apr 26, 2018: AtriCure Reports First Quarter 2018 Financial Results
  • 6.18 Apr 26, 2018: Stryker reports first quarter 2018 operating results
  • 6.19 Apr 25, 2018: KARL STORZ OR1 Operating Rooms - Now Assisting the Surgical Team at Spital Thun, Switzerland
  • 6.20 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
  • 6.21 Apr 04, 2018: Namal Nawana appointed Chief Executive Officer of Smith & Nephew
  • 6.22 Mar 29, 2018: AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
  • 6.23 Mar 20, 2018: Governor Abbott Announces Smith & Nephew Adding New Jobs In Fort Worth
  • 6.24 Mar 08, 2018: Baylis Medical wins Best Managed Companies award
  • 6.25 Mar 01, 2018: Smith & Nephew: Change in Directorate
  • 6.26 Feb 27, 2018: Integra LifeSciences Reports Fourth Quarter and Full-Year 2017 Financial Results
  • 6.27 Feb 26, 2018: AtriCure Announces Fourth Quarter and Full Year 2017 Financial Results
  • 6.28 Feb 20, 2018: AtriCure Names Scott Drake Board Chairman

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
Back to Top